Cargando…
A Randomized Pilot Study of Atractylenolide I on Gastric Cancer Cachexia Patients
We determined the therapeutic efficacy of atractylenolide I (ATR), extracted from largehead atractylodes rhizome, in managing gastric cancer cachexia (GCC), and interpreted its probable pharmacological mechanism via investigating tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin...
Autores principales: | Liu, Yi, Jia, Zhongwu, Dong, Lei, Wang, Rui, Qiu, Genquan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529387/ https://www.ncbi.nlm.nih.gov/pubmed/18830451 http://dx.doi.org/10.1093/ecam/nem031 |
Ejemplares similares
-
Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I
por: Zhang, Wan-li, et al.
Publicado: (2019) -
Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL‐6 and tumour‐derived extracellular vesicles
por: Fan, Meng, et al.
Publicado: (2022) -
Anti-tumor effects of Atractylenolide I on bladder cancer cells
por: Yu, Rui, et al.
Publicado: (2016) -
Correction to: Anti-tumor effects of Atractylenolide I on bladder cancer cells
por: Yu, Rui, et al.
Publicado: (2018) -
Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells
por: Long, Fangyi, et al.
Publicado: (2017)